Center for Hemorrhagic and Thrombotic Diseases, General University Hospital of Udine, Udine, Italy.
J Thromb Thrombolysis. 2010 May;29(4):459-64. doi: 10.1007/s11239-009-0384-5.
Retinal vein occlusion (RVO) is the second most common retinal vein disease and an important cause of blindness and visual morbidity. Systemic risk factors are commonly associated with RVO, while unclear it is the role of the thrombophilic and coagulation disorders. To evaluate "classic" and "emerging" risk factors, and to establish a good treatment for RVO. Fifty patients, 31 males and 19 females, with RVO were selected for our study. RVO patients were divided into two groups: those with central retinal vein occlusion (CRVO) and those with branch retinal vein occlusion (BRVO). All patients were subjected to an anamnestic investigation and were tested for thrombophilia, coagulation disorders and hyperlipidemia. Treatment and prophylaxis were evaluated. We have named "classic" the systemic risk factors associated with RVO and "emerging" those risk factors, haemostasis related, not clearly associated with RVO. RVO occurs more commonly in patients aged over 50. "Emerging" risk factors were more frequent in CRVO, "classic" in BRVO. Hyperhomocysteinemia is the most common "emerging" risk factor related to RVO. 71.4% of tested patients had hypercholesterolemia. Treatment with LMWH would appear to be safe and effective, but the small number of patients considered not allow us a definitive evaluation of its efficacy. Although our study has shown the correlation between RVO and the "emerging" risk factors, more studies are necessary to better know the real role of thrombophilic and coagulation disorders in this disease and to determine a specific protocol for the treatment and prophylaxis of RVO.
视网膜静脉阻塞（RVO）是第二常见的视网膜静脉疾病，是失明和视力受损的重要原因。全身性危险因素通常与 RVO 相关，但血栓形成和凝血障碍的作用尚不清楚。为了评估“经典”和“新兴”危险因素，并为 RVO 建立良好的治疗方法。我们选择了 50 名 RVO 患者进行研究，其中男性 31 名，女性 19 名。RVO 患者分为中央视网膜静脉阻塞（CRVO）和分支视网膜静脉阻塞（BRVO）两组。所有患者均进行病史调查，并进行血栓形成倾向、凝血障碍和高脂血症检查。评估治疗和预防措施。我们将与 RVO 相关的系统性危险因素命名为“经典”，将与止血相关、与 RVO 无明确关联的危险因素命名为“新兴”。RVO 更常见于 50 岁以上的患者。“新兴”危险因素在 CRVO 中更为常见，“经典”危险因素在 BRVO 中更为常见。高同型半胱氨酸血症是与 RVO 相关的最常见“新兴”危险因素。71.4%的患者胆固醇升高。低分子肝素（LMWH）治疗似乎安全有效，但考虑到患者人数较少，我们无法对其疗效进行明确评估。尽管我们的研究表明 RVO 与“新兴”危险因素之间存在相关性，但需要更多的研究来更好地了解血栓形成倾向和凝血障碍在这种疾病中的真正作用，并确定 RVO 的治疗和预防方案。
